EFFECT OF VASOPRESSORS ON FLUID CHALLENGE PERSISTENCE AN OBSERVATIONAL STUDY IN PATIENTS UNDERGOING LAPAROTOMY.
NCT ID: NCT04934345
Last Updated: 2021-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2021-09-01
2022-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this context, the effect of adding a vasopressor to keep the arterial pressure between predefined ranges may impact on the persistence of stroke volume (SV) changes after FC administration. In fact, both the effect on arterial elastance and venous return may increase the persistence of SV increase, which is know to drop to baseline pre-FC values within fw minutes after FC administration.
This single-centre observational study, in elective patients scheduled for elective laparotomy, hypothesizes that intraoperative norepinephrine infusion would prolong the effect of FC administration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlation Between ΔPP/HR and ΔSV During Fluid Challenge.
NCT02439242
Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac Surgery
NCT06934798
The Hemodynamic Effects of Vasopressin in Patients With Fontan Physiology
NCT04463394
Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery
NCT03483753
HIgh Versus STAndard Blood Pressure Target in Hypertensive High-risk Patients Undergoing Major Abdominal Surgery
NCT05637606
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The fluid challenge (FC) is defined as a small amount of fluid given in a short period of time to assess whether the preload reserve of the patient can increase SV with further administration of fluids. A number of studies performed in the operating room evaluated the hemodynamic effects of FC solely considering the effect before and after the infusion. Recently, Aya demonstrated that at least 4 ml kg-1 should be infused to effectively challenge the preload, additionally showing that the hemodynamic effect of the FC is dissipated within 10 minutes, in both responders and in non-responders.
The approach of Aya et al. considers the FC as a drug evoking a systemic response on flow (i.e. SV) and pressure variables \[i.e. systolic arterial pressure (SAP)\]. Accordingly, the pharmacodynamic effect is evaluated by considering the magnitude (i.e. the maximal changes from baseline obtained for a specific variable), the global effect \[i.e. considering the area under the curve (AUC) obtained by plotting the changes overtime\] and the persistence of the hemodynamic response after the end of FC administration. The infusion time of FC administration, which ranges in the literature between 5 and 30 minutes, may influence the magnitude of SV response and, in turn, the amount of patients defined as fluid responders . Since several intraoperative pathways of hemodynamic optimization are based on the response to repeated FCs, a prolonged infusion time may potentially affect fluid responsiveness and, in turn, wrongly drive intraoperative fluid management and eventually affect postoperative outcomes.
Since FC is a test embedding at least three variables (i.e. the amount of fluid; the time needed to complete the administration and the SV change threshold used to define a positive response), the role of a one single component on the final outcome can be addressed only by keeping fixed the others. Our group recently investigated the role of the infusion rate in a multicentre study (under revision at the timing of writing this protocol) and our research is now focused on the assessment of the role of the vascular tone in the persistence of the FC effect overtime. The previous study demonstrated that the rate of infusion impact on FC response, however another crucial issue is related to the persistence of the effect of the FC on the SV. In fact, the SV is determined by the interplay between cardiac function and arterial load. Diastolic filling depends on venous return, which is determined by the "stressed volume" and venous compliance. Systolic cardiac function depends on both cardiac factors and arterial load and is predominantly determined by arterial elastance (Ea) and resistance. For this reason, the effect of a vasopressor (i.e. the norepinephrine, the most widely used) may impact on the persistence of the increase of the SV after FC administration.
This single-centre observational study, in elective patients scheduled for elective laparotomy, hypothesizes that intraoperative norepinephrine infusion would prolong the effect of FC administration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FC administration
* All the patients receive crystalloids at 4 ml/kg/hour as maintenance fluid during surgery, according to standard practice.
* After the first episode of hypotension (MAP \< 65 mmHg) the PPV is checked.
* PPV ≥ 13% - FC (4 ml/kg of crystalloids administered in 10')
* PPV \< 13% - start norepinephrine (starting dose - 0.05 mcg/kg/min). In this group, the FC will be administered during an episode of intraoperative hypotension during NE infusion.
Fluid challenge
The fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fluid challenge
The fluid challenge consists of a bolus of 4 ml/kg of crystalloids, administered over 10 minutes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* reduced left (ejection fraction \< 30%) or right (systolic peak velocity of tricuspid annular motion \< 0.17 m/s) ventricular systolic function.
Once enrolled, the patient can be additionally excluded due to the occurrence of one of the following intraoperative conditions:
1. significant bleeding (more than 500 ml in ½ hour)
2. recurrent extrasystoles
3. persistent low quality of the arterial signal affecting hemodynamic monitoring measurements
4. intraoperative hemodynamic instability requiring the persistent use of vasopressors.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Humanitas Clinical and Research Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Humanitas Research Hospital
Rozzano, Milano, Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Aya HD, Ster IC, Fletcher N, Grounds RM, Rhodes A, Cecconi M. Pharmacodynamic Analysis of a Fluid Challenge. Crit Care Med. 2016 May;44(5):880-91. doi: 10.1097/CCM.0000000000001517.
Vincent JL. Fluid management in the critically ill. Kidney Int. 2019 Jul;96(1):52-57. doi: 10.1016/j.kint.2018.11.047. Epub 2019 Mar 4.
Monnet X, Teboul JL. Assessment of fluid responsiveness: recent advances. Curr Opin Crit Care. 2018 Jun;24(3):190-195. doi: 10.1097/MCC.0000000000000501.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NORA_FC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.